Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof

Inventors

Han, Sangdon • ZHU, Yunfei • Kim, Sun Hee • Zhao, Jian • Wang, Shimiao

Assignees

Crinetics Pharmaceuticals Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-10981894-B2

Patent

Publication Date

2021-04-20

Expiration Date


Abstract

Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.

Core Innovation

The invention claims a compound genus of Formula (IX), or a pharmaceutically acceptable salt or solvate thereof, acting as melanocortin receptor modulators and specifically melanocortin subtype-2 receptor (MC2R) antagonists. The scaffold specifies V as CH and X1 as CR6, alongside defined substituents including hydrogen, halogen, alkyl, fluoroalkyl, heteroalkyl, carbocycle, heterocycle, aryl, and heteroaryl groups. Disclosed embodiments include substituted piperazine derivatives, biphenyl, bipyridine, and pyrazine carboxamides, saturated heterocycles, and ethoxy-substituted aryl groups.

The compounds and pharmaceutical compositions modulate MC2R activity in a mammal to treat conditions benefiting from MC2R modulation, such as Cushing’s syndrome. Reported MC2R radioligand-binding screening result demonstrates potency, with Ki values below 10 nM and between 10 and 100 nM. Because background, summary, and abstract sections are omitted from the supplied content, the technical problem being addressed is not explicitly described in the patent.

Claims Coverage

The provided claims identify one independent claim, claim 1, which recites three inventive features directed to compounds of Formula (IX) and their structural alternatives.

Formula (IX) compound genus and forms

Claim 1 recites a compound of Formula (IX), or a pharmaceutically acceptable salt or solvate thereof.

Defined scaffold alternatives

The scaffold specifies V as CH; X1 as CR6, wherein R6 is H or F; and R2 and R3 as hydrogen or taken together with their attached carbon atom to form —C(═O)—.

Variable substituent groups

The claim defines alternatives for Ra, Rb, Rc, RB, Rd, Re, Rf, R4, R7, R8, R9, and R10, including hydrogen, halogen, alkyl, fluoroalkyl, heteroalkyl, carbocycle, heterocycle, aryl, and heteroaryl groups, with further ring-forming and substituent alternatives.

The independent claim covers the defined Formula (IX) compound genus and its pharmaceutically acceptable salts and solvates, structurally defined by the recited scaffold and substituent alternatives. Dependent claims encompass pharmaceutical compositions comprising an excipient, methods of modulating MC2R activity, and treatments for conditions benefiting from MC2R modulation, including Cushing’s syndrome.

Stated Advantages

Not explicitly described in patent.

Documented Applications

A pharmaceutical composition comprising a claimed compound of Formula (IX), salt, or solvate and at least one pharmaceutically acceptable excipient, suitable for administration routes including oral administration.

A method of modulating melanocortin subtype-2 receptor (MC2R) activity in a mammal by administering a claimed compound, salt, or solvate.

Treatment of a mammal with a condition benefiting from MC2R modulation, including Cushing’s syndrome and disease, ectopic ACTH syndrome, congenital adrenal hyperplasia, depressive illness, and septic shock.

Use of Formula (I) compounds to modulate melanocortin receptor activity.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.